The target audience for this program includes basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice, as well as those involved in manufacturing of cellular therapies.
At the conclusion of this activity, participants should be able to:
This program is not eligible for continuing education credit.
- Explain the status and direction of cellular therapies for cancer treatment
- Identify highly relevant challenges and questions facing the translation of cellular therapies from preclinical to clinical settings
- Describe cellular therapies employing immune cells other than T cells
- Summarize novel technologies that are enabling broader application of cellular therapies for cancer